Viking Therapeutics (VKTX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$714.6 million.
- Viking Therapeutics' Enterprise Value rose 2320.09% to -$714.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$714.6 million, marking a year-over-year increase of 2320.09%. This contributed to the annual value of -$902.6 million for FY2024, which is 14928.59% down from last year.
- According to the latest figures from Q3 2025, Viking Therapeutics' Enterprise Value is -$714.6 million, which was up 2320.09% from -$807.7 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Enterprise Value ranged from a high of -$135.7 million in Q1 2023 and a low of -$963.0 million during Q1 2024
- In the last 5 years, Viking Therapeutics' Enterprise Value had a median value of -$362.1 million in 2023 and averaged -$486.0 million.
- Per our database at Business Quant, Viking Therapeutics' Enterprise Value soared by 6135.48% in 2023 and then crashed by 60982.43% in 2024.
- Viking Therapeutics' Enterprise Value (Quarter) stood at -$202.1 million in 2021, then grew by 23.07% to -$155.5 million in 2022, then crashed by 132.87% to -$362.1 million in 2023, then tumbled by 149.29% to -$902.6 million in 2024, then grew by 20.83% to -$714.6 million in 2025.
- Its Enterprise Value stands at -$714.6 million for Q3 2025, versus -$807.7 million for Q2 2025 and -$851.9 million for Q1 2025.